share_log

HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Adjusts Price Target To $10

HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Adjusts Price Target To $10

HC Wainwright & Co.重申买入SAB Biotherapeutics,将目标股价调整至10美元
Benzinga ·  01/08 06:22

HC Wainwright & Co. analyst Edward White reiterates SAB Biotherapeutics (NASDAQ:SABS) with a Buy, adjusts target to $10 from $1.

HC Wainwright & Co. 分析师爱德华·怀特重申SAB Biotherapeutics(纳斯达克股票代码:SABS)的买入,将目标从1美元调整至10美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发